NAUT

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Nautilus Biotechnolgy (NAUT – Research Report), with a price target of $6.00. The company's shares closed last Wednesday at $2.89, close to its 52-week low of $2.53. According to TipRanks.com, Savant is a 1-star analyst with an average return of -5.1% and a 42.7% success rate. Savant covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Adaptive Biotechnologies, and Pacific Biosciences. Nautilus Biotechnolgy has an analyst consensus of Moderate Buy, with a price target consensus of $6.33, implying an 119.8% upside from current levels.
https://www.tipranks.com/news/blurbs/nautilus-biotechnolgy-naut-gets-a-hold-rating-from-morgan-stanley?utm_source=advfn.com&utm_medium=referral